These molecular classifications with major predictive and prognostic implications opened the way to histologic-independent personalized therapies, such as poly-ADP ribose polymerase (PARP) inhibitors for the treatment of tumors with mutations in BRCA1 and BRCA2 genes (present in up to 5% of breast cancer patients [31]) by preventing tumor cells with BRCA1/BRCA2 mutations from repairing DNA damage caused by cytotoxic chemotherapy [32]. Here, BRCA2 is linked to neoplasm.